Author: [email protected]

20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Theratechnologies has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Press release Theratechnologies, FEB 27, 2014, View Source [SID1234500172]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program

Clovis Oncology aims for its first New Drug Application (NDA) submission by 2015. Lined up is a global Phase 3 registration study for rucaparib and plans to initiate registration studies for CO-1686 in the second quarter of 2014 (Press release Clovis Oncology, FEB 27, 2014, View Source [SID:1234500190]).

Clovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program

Clovis Oncology aims for its first New Drug Application (NDA) submission by 2015. Lined up is a global Phase 3 registration study for rucaparib and plans to initiate registration studies for CO-1686 in the second quarter of 2014 (Press release Clovis Oncology, FEB 27, 2014, View Source [SID:1234500190]).

Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G305 Cancer Immunotherapy Agent

On February 27, 2014 Immune Design announced treatment of the first patient in a Phase 1 clinical trial of ID-G305 (Press release Immune Design, FEB 27, 2014, View Source [SID:1234500179]).
The Phase 1 open label, dose-escalation trial is designed to evaluate the safety, tolerability and immunogenicity of ID-G305 in patients with unresectable, relapsed, or metastatic cancer expressing the NY-ESO-1 antigen, including melanoma, sarcoma, lung, ovarian or breast cancer. The trial is being conducted in up to 18 patients at several clinical centers in the United States.

Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone

On February 27, 2014 Epizyme reported the achievement of the lead candidate selection milestone for one of the histone methyltransferase (HMT) targets in the company’s collaboration with GSK (Press release Epizyme, FEB 27, 2014, View Source [SID:1234500178]). This achievement triggers a milestone payment of $2 million and follows the announcement in January 2014 of the achievement of a development candidate milestone for another of the HMT targets in the collaboration, which earned Epizyme a $4 million milestone payment.